Literature DB >> 8410567

Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407.

P L Wang1, T P Johnston.   

Abstract

To enhance the physical stability of two model proteins during solution agitation, we investigated the interaction of the nonionic surfactant poloxamer 407 (Pluronic F-127) with each protein. Vigorous agitation of aqueous solutions of interleukin-2 and urease which contained no poloxamer 407 and were maintained at 4 degrees C resulted in a greater than 50% loss in the biological activity at 12 and 24 hours, respectively. Similar aqueous solutions which were maintained at 4 degrees C and contained either urease or interleukin-2 and poloxamer 407 at a concentration of 10% w/w and 0.5% w/w, respectively lost negligible biological activity when left undisturbed for 96 hours. Moreover, when aqueous solutions of urease and interleukin-2 which contained poloxamer 407 at a concentration of 10% w/w and 0.5% w/w, respectively were maintained at 4 degrees C and subjected to agitation for 96 hours, no significant loss in the biological activity was observed for either protein. In addition, urease was observed to have increased enzymatic activity at early time points regardless of the hydrodynamic solution conditions and poloxamer 407 concentrations evaluated. In contrast, a negligible enhancement in the biological activity of interleukin-2 was observed when aqueous solutions of the protein were exposed to similar hydrodynamic conditions employed for urease solutions, but different poloxamer concentrations (0% w/w vs. 0.5% w/w). Results of molar ellipticity, [theta], versus wavelength, lambda, profiles using CD spectropolarimetry on individual aqueous solutions of both proteins containing 2% w/w poloxamer 407 were in close agreement to spectrum obtained with each protein in pH = 7 phosphate buffer (PB).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410567

Source DB:  PubMed          Journal:  J Parenter Sci Technol        ISSN: 0279-7976


  9 in total

Review 1.  A review of poloxamer 407 pharmaceutical and pharmacological characteristics.

Authors:  Gilles Dumortier; Jean Louis Grossiord; Florence Agnely; Jean Claude Chaumeil
Journal:  Pharm Res       Date:  2006-11-11       Impact factor: 4.200

2.  Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives.

Authors:  P Johansen; Y Men; R Audran; G Corradin; H P Merkle; B Gander
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

3.  Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.

Authors:  Neeta Jain-Gupta; Araceli Contreras-Rodriguez; Ramesh Vemulapalli; Sharon G Witonsky; Stephen M Boyle; Nammalwar Sriranganathan
Journal:  FEMS Immunol Med Microbiol       Date:  2012-12

4.  Role of a novel excipient poly(ethylene glycol)-b-poly(L-histidine) in retention of physical stability of insulin in aqueous solutions.

Authors:  Ajay Taluja; You Han Bae
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

5.  In vitro and in vivo evaluation of topical formulations of spantide II.

Authors:  Loice Kikwai; R Jayachandra Babu; Renata Prado; Alexandra Kolot; Cheryl A Armstrong; John C Ansel; Mandip Singh
Journal:  AAPS PharmSciTech       Date:  2005-10-31       Impact factor: 3.246

Review 6.  Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review.

Authors:  Mohammad Ariful Islam; Jannatul Firdous; Yun-Jaie Choi; Cheol-Heui Yun; Chong-Su Cho
Journal:  Int J Nanomedicine       Date:  2012-12-13

7.  3D Bioprinted Scaffolds Containing Mesenchymal Stem/Stromal Lyosecretome: Next Generation Controlled Release Device for Bone Regenerative Medicine.

Authors:  Elia Bari; Franca Scocozza; Sara Perteghella; Marzio Sorlini; Ferdinando Auricchio; Maria Luisa Torre; Michele Conti
Journal:  Pharmaceutics       Date:  2021-04-08       Impact factor: 6.321

8.  Sustained delivery of IL-1Ra from PF127-gel reduces hyperglycemia in diabetic GK-rats.

Authors:  Muhammad Sajid Hamid Akash; Kanwal Rehman; Hongying Sun; Shuqing Chen
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

Review 9.  Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.

Authors:  S Basavaraj; Guru V Betageri
Journal:  Acta Pharm Sin B       Date:  2014-01-24       Impact factor: 11.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.